Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors
| Autor: | Timothy J. Opperman, Zachary D. Aron, Donald T. Moir, Terry L. Bowlin |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.drug_class Antibiotics medicine.disease_cause Type three secretion system Microbiology 03 medical and health sciences 0302 clinical medicine Bacterial Proteins Drug Resistance Multiple Bacterial Drug Discovery Type III Secretion Systems Medicine Animals Humans Pharmacology Innate immune system biology business.industry Pseudomonas aeruginosa Membrane Transport Proteins biology.organism_classification Enterobacteriaceae Anti-Bacterial Agents Multiple drug resistance 030104 developmental biology 030220 oncology & carcinogenesis Bacterial virulence Efflux business Gram-Negative Bacterial Infections |
| Zdroj: | Drug discovery today. 26(9) |
| ISSN: | 1878-5832 |
| Popis: | The increasing prevalence of multidrug-resistant (MDR) bacterial infections has created a crucial need for new therapeutics that avoid or minimize existing resistance mechanisms. In this review, we describe the development of novel classes of small-molecule adjunctive agents targeting either a bacterial virulence factor, the Pseudomonas aeruginosa type III secretion system (T3SS), or an intrinsic resistance factor, resistance-nodulation-cell division superfamily (RND) efflux pumps of the Enterobacteriaceae. These agents are designed to be administered with antibacterials to improve their efficacy. T3SS inhibition rescues host innate immune system cells from injection with bacterial toxins, whereas RND efflux pump inhibition increases antibiotic susceptibility, in both cases improving the efficacy of the combined antibacterial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect